findmyKOL

David Eichenbaum, MD

Enriched profile

Partner and Director of Research · Retina Vitreous Associates of Florida

ORCIDNPI
Region🇺🇸 St Petersburg, FL · Southeast · United StatesSpecialtyOphthalmologyFocusRetinal Diseases and Treatments+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

David Eichenbaum is Partner and Director of Research at Retina Vitreous Associates of Florida. OpenAlex indexes 92 publications with 2,524 citations (h-index 22); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 1 Sept 2026

David A. Eichenbaum, MD, is Partner and Director of Research at Retina Vitreous Associates of Florida. The public record shows 92 publications with 2,524 citations (h-index 22), centered on Retinal Diseases and Treatments, Ocular Diseases and Behçet’s Syndrome, Retinal and Optic Conditions. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 48 companies.

  • Most recent indexed publication: 2025 · Journal of vitreoretinal diseases
  • Top research focus: Retinal Diseases and Treatments
  • 5 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 48 companies

Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Macular Degeneration (AMD)4 trialsDiabetic Complications2 trialsDiabetic Retinopathy / DME2 trialsEdema2 trialsMacular Edema2 trialsDiabetic Retinopathy1 trialGeographic Atrophy1 trialAtrophy1 trialRetinal Vein Occlusion1 trial

Research focus

OpenAlex concept fingerprint
Retinal Diseases and TreatmentsOcular Diseases and Behçet’s SyndromeRetinal and Optic ConditionsRetinal Imaging and AnalysisOphthalmology and Visual Impairment Studies

Drugs & molecules

across trials, industry payments and publications
Eyleageneric · AfliberceptClinical trialsIndustry payments96Publications6Syfovregeneric · PegcetacoplanClinical trialsIndustry payments93Publications1Iluviengeneric · FluocinoloneClinical trialsIndustry payments90Publications1

Works with

trial sponsors and companies reporting payments
Regeneron Healthcare Solutions, Inc.Clinical trialsIndustry payments224Genentech USA, Inc.Clinical trialsIndustry payments201Apellis Pharmaceuticals, Inc.Clinical trialsIndustry payments179

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
92publications

Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.

2,524citations

Total citations across indexed works.

22h-index

Hirsch index (OpenAlex). i10-index 40.

Clinical & industry

trials, payments and federal funding
5clinical trials

Investigator role on registered studies.

View trials
48companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 1 Sept 2026

Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 1 Sept 2026

48 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    58.8%
    Antineovascularisation agents55.8%
    Faricimab-svoa100%
    Part B, office-administered171 patients
    Complement Inhibitor2%
    Avacincaptad pegol100%
    Part B, office-administered15 patients
  • Nervous system

    36.4%
    Ester Local Anesthetic36.4%
    Chloroprocaine hcl ophthalmic100%
    Part B, office-administered21 patients
  • Cancer & immunology

    4.7%
    Complement Inhibitor3.9%
    Pegcetacoplan100%
    Part B, office-administered34 patients
    Vascular Endothelial Growth Factor Inhibitor0.8%
    Aflibercept100%
    Part B, office-administered110 patients
4 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 1 Sept 2026

1 congress contribution (2022) across ADA per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 1 Sept 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 1 Sept 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Charles C. Wykoff18Arshad M. Khanani16Jeffrey S. Heier14

Online presence

Updated 1 Sept 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/david-eichenbaum-034a6549

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    modernretina.com/view/eichenbaum-acorns-mentorship-momentum-and-the-making-of-a-retina-podcast

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →modernretina.com

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/retina_today/reel/CxleCRvpgen

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com
  • Other

    rvaf.com/ourdocs/eichenbaum

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rvaf.com
  • Other

    asrs.org/find-a-specialist/profile/2289/David-A-Eichenbaum

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →asrs.org
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 1 Sept 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    American Board of Ophthalmology

    2007
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com
  • MD

    University of South Florida (Medical Honors Program)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org
  • Ophthalmology residency

    University of South Florida (Chief Resident)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org
  • Surgical Retina Fellowship

    Tufts New England Eye Center / Ophthalmic Consultants of Boston

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org

Editorial & leadership roles

journal and society appointments
  • 2023-2024 President

    Florida Society of Ophthalmology

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdeye.org
  • Guest Editor

    "Switching Anti-VEGF Agents for AMD Treatment" supplement, Retinal Physician

    2021
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →retinalphysician.com
  • Chair

    Retina Sub-Specialty section, Florida Society Masters Meeting

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org
  • Guest of Honor

    New England Ophthalmological Society

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org
  • Alumnus of the Year

    USF Department of Ophthalmology

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org
3 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • Guest

    "The Retina Radar" with Dr. Arshad Khanani: nAMD Management in 2024 (YouTube)

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
  • Guest

    "New Insight" podcast with Veeral Sheth, MD: Reengaging the Retina Community in 2024

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com
  • Host

    "Eichenbaum Acorns" podcast/interview series (Modern Retina)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →modernretina.com
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.